Answers are grounded in this paper and cite their sources.
Patients with malignant cancer confirmed histologically at antecedent treatment underwent adoptive immuno-cell therapy at Meditopia Numazu Clinic between November 2007 and November 2010. Written informed consent was obtained from all patients before the start of immuno-cell therapy. The clinical data of 38 consecutive patients (18 men, 20 women; mean age, 64 years; age range 39-83 years) were evaluated. The Eastern Cooperative Oncology Group (ECOG) performance status [1] at the beginning of the treatment was PS-0 in 18 patients, PS-1 in 17, PS-2 in 2, and PS-3 in 2. All patients underwent at least one course of treatment consisting of 6 infusions of ALs (3-10 x 109) and/or matured DCs (1-10 9x106) intravenously or sub-cutaneously at intervals of around 2 weeks. The patients also received additional conventional
No takes yet. Share an insight, caveat, or question.
A 2018 study studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: